ES2196308T3 - Derivado de 2-cianoiminoimidazol que inhiben la pde iv. - Google Patents

Derivado de 2-cianoiminoimidazol que inhiben la pde iv.

Info

Publication number
ES2196308T3
ES2196308T3 ES97910380T ES97910380T ES2196308T3 ES 2196308 T3 ES2196308 T3 ES 2196308T3 ES 97910380 T ES97910380 T ES 97910380T ES 97910380 T ES97910380 T ES 97910380T ES 2196308 T3 ES2196308 T3 ES 2196308T3
Authority
ES
Spain
Prior art keywords
rent
replaced
hydrogen
halo
trifluorometilo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97910380T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Francisco Javi Fernandez-Gadea
Jose Ignacio Andres-Gil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2196308T3 publication Critical patent/ES2196308T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE 2 CIANOIMINOIMIDAZOL DE FORMULA (I), A SUS FORMAS DE N - OXIDO, SUS SALES DE ADICION FARMACEUTICAMENTE ACEPTABLES Y SUS FORMAS ESTEREOQUIMICAMENTE ISOMERICAS, DONDE R 1 Y R 2 CADA UNO I NDEPENDIENTEMENTE, SON HIDROGENO, ALQUILO C 1-6 , DIFLUOROMETILO, TRIFLUOROMETILO, CICLOALQUILO C 3-6 , UN HETEROCIC LO DE 5, 6 O 7 MIEMBROS, QUE CONTIENE UNO O DOS HETEROATOMOS SELECCIONADOS A PARTIR DE OXIGENO, AZUFRE O NITROGENO; INDANILO; 6,7 - DIHIDRO - 5H - CICLOPENTAPIRIDINILO; BICICLO[2.2.1] - 2 - HEPTENILO; BICICLO[2.2.1]HEPTANILO; ALQUILSULFONILO C 1-6 ; ARILSULFONILO O ALQUILO C 1-10 SUSTITUIDO; R 3 ES HIDROGENO, HALO O ALQUILOXI C 1-6 ; R 4 ES HIDROGENO, HALO, ALQUILO C 1-6 , TRIFLUOROMETILO; CICLOALQUILO C SUB,3-6 ; CARBOXILO; ALCOXICARBONILO C 1-4 ; CICLOALQUILAMINO CARBONILO C 36 ; ARILO; HET 1 ; O ALQUILO C 1-6 SUSTITUIDO; O R 4 ES - O - R 7 O - NH - R 8 ; R S UP,5 ES HIDROGENO, HALO, HIDROXILO, ALQUILO C 1-6 O ALQUILOXI C 1-6 ; R 6 ES HIDROGENOO ALQUILO C 1-4 ; O R 4 Y R 6 O R 4 Y R 5 , CONJUNTAMENTE, PUEDEN FORMAR UN RADICAL BIVALENTE; - A - B - ES - CR 10 = CR 11 - O - CHR 10 CHR 11 -; L ES HIDROGENO; ALQUILO C 1-6 ; ALQUILCARBONILO C 1-6 ; ALQUILOXICARBONI LO C 1-6 ; ALQUILO C 1-6 SUSTITUIDO; ALQUENILO C 3-6 ; ALQUENILO C 3-6 SUSTITUIDO; PIPERIDINILO; PIPERIDIN ILO SUSTITUIDO; ALQUILSULFONILO C 1-6 O ARILSULFONILO. DICHOS COMPUESTOS PRESENTAN ACTIVIDAD INHIBIDORA DE PDE IV Y DE CITOQUINA. LA INVENCION SE REFIERE TAMBIEN A LOS PROCEDIMIENTOS DE PREPARACION DE LOS COMPUESTOS DE FORMULA (I) Y A COMPOSICIONES FARMACEUTICAS DE LOS MISMOS.
ES97910380T 1996-10-02 1997-09-24 Derivado de 2-cianoiminoimidazol que inhiben la pde iv. Expired - Lifetime ES2196308T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96202749 1996-10-02

Publications (1)

Publication Number Publication Date
ES2196308T3 true ES2196308T3 (es) 2003-12-16

Family

ID=8224456

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97910380T Expired - Lifetime ES2196308T3 (es) 1996-10-02 1997-09-24 Derivado de 2-cianoiminoimidazol que inhiben la pde iv.

Country Status (30)

Country Link
US (1) US6051718A (es)
EP (1) EP0934280B1 (es)
JP (1) JP3068208B2 (es)
KR (1) KR100520002B1 (es)
CN (1) CN1106387C (es)
AR (1) AR008875A1 (es)
AT (1) ATE236884T1 (es)
AU (1) AU719561B2 (es)
BG (1) BG64278B1 (es)
BR (1) BR9712256B1 (es)
CA (1) CA2267322C (es)
CY (1) CY2380B1 (es)
CZ (1) CZ297474B6 (es)
DE (1) DE69720757T2 (es)
DK (1) DK0934280T3 (es)
EE (1) EE03825B1 (es)
ES (1) ES2196308T3 (es)
HU (1) HU225158B1 (es)
IL (2) IL129298A0 (es)
MY (1) MY116980A (es)
NO (1) NO312960B1 (es)
NZ (1) NZ334971A (es)
PL (1) PL194673B1 (es)
PT (1) PT934280E (es)
RU (1) RU2180902C2 (es)
SI (1) SI0934280T1 (es)
SK (1) SK285878B6 (es)
TR (1) TR199900732T2 (es)
UA (1) UA62939C2 (es)
WO (1) WO1998014432A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4778612B2 (ja) 1998-04-01 2011-09-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pdeiv阻害ピリジン誘導体
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
RU2270192C2 (ru) * 2001-04-19 2006-02-20 Эйсай Ко., Лтд. Производные 2-иминопирролидина
KR20040007583A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 연골 질환의 재생치료용 조성물
US20040220227A1 (en) * 2001-07-11 2004-11-04 Shinji Ina Remedies for allergic eye diseases
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
PT1908463E (pt) 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
EP1602646A4 (en) 2003-02-19 2010-07-28 Eisai R&D Man Co Ltd PROCESS FOR PREPARING CYCLIC BENZAMIDINE DERIVATIVES
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
CA2985787A1 (en) * 2012-06-07 2013-12-12 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
GB2533925A (en) * 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
CN109438434B (zh) * 2018-11-19 2021-05-04 华南农业大学 一种含噁唑环的2-氰基亚氨基噻唑烷类化合物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784461B2 (ja) * 1986-12-19 1995-09-13 日本バイエルアグロケム株式会社 殺虫性ニトロイミノ又はシアノイミノ化合物
JPH05310650A (ja) * 1991-08-22 1993-11-22 Nippon Soda Co Ltd 新規なアミン誘導体、その製造方法及び殺虫剤
IL106517A0 (en) * 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
DK0672031T3 (da) * 1992-12-02 2003-06-10 Pfizer Catecholdiethere som selektive PDE IV-inhibitorer
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
WO1995005386A1 (en) * 1993-08-19 1995-02-23 Smithkline Beecham Corporation Phenethylamine compounds
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
JP3056788B2 (ja) * 1994-06-24 2000-06-26 ユーロ−セルティーク,エス.エイ. ホスホジエステラーゼivの阻害化合物および阻害方法
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
TW375612B (en) * 1995-04-06 1999-12-01 Janssen Pharmaceutica Nv 1,3-dihydro-2H-imidazol-2-one derivatives for the treatment of disease states related to an abnormal enzymatic or catalytic activity of phosphodiesterase type IV, preparation thereof and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
ATE236884T1 (de) 2003-04-15
PT934280E (pt) 2003-08-29
PL332573A1 (en) 1999-09-27
AR008875A1 (es) 2000-02-23
CN1232456A (zh) 1999-10-20
AU719561B2 (en) 2000-05-11
BG64278B1 (bg) 2004-08-31
SK285878B6 (sk) 2007-10-04
MY116980A (en) 2004-04-30
JP2000503678A (ja) 2000-03-28
NO312960B1 (no) 2002-07-22
BR9712256A (pt) 1999-08-24
WO1998014432A1 (en) 1998-04-09
CZ102899A3 (cs) 1999-07-14
US6051718A (en) 2000-04-18
EE9900112A (et) 1999-10-15
CN1106387C (zh) 2003-04-23
NO991560L (no) 1999-06-02
HUP9904063A3 (en) 2000-11-28
CY2380B1 (en) 2004-06-04
RU2180902C2 (ru) 2002-03-27
BG103220A (en) 1999-11-30
JP3068208B2 (ja) 2000-07-24
DE69720757D1 (de) 2003-05-15
NZ334971A (en) 2000-09-29
HK1020344A1 (en) 2000-04-14
EP0934280A1 (en) 1999-08-11
CA2267322C (en) 2007-11-06
IL129298A0 (en) 2000-02-17
BR9712256B1 (pt) 2011-04-19
EE03825B1 (et) 2002-08-15
PL194673B1 (pl) 2007-06-29
NO991560D0 (no) 1999-03-30
CZ297474B6 (cs) 2006-12-13
SK34499A3 (en) 2000-04-10
CA2267322A1 (en) 1998-04-09
SI0934280T1 (en) 2003-12-31
EP0934280B1 (en) 2003-04-09
HUP9904063A2 (hu) 2000-09-28
UA62939C2 (uk) 2004-01-15
KR20000029964A (ko) 2000-05-25
TR199900732T2 (xx) 1999-08-23
DE69720757T2 (de) 2004-03-04
IL129298A (en) 2006-04-10
DK0934280T3 (da) 2003-07-21
AU4779297A (en) 1998-04-24
HU225158B1 (en) 2006-07-28
KR100520002B1 (ko) 2005-10-13

Similar Documents

Publication Publication Date Title
DE69710319D1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
ES2150918T3 (es) 1h-imidazo(4,5-c)quinolin-4-aminas 1-sustituidas; compuestos intermedios y composiciones farmaceuticas.
NO20020725D0 (no) Celleadhesjonsinhibitorer
TR200102136T2 (tr) Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler.
DK0928788T3 (da) Imidazolidin-4-on-derivater, der er nyttige som anticancer-midler
NO985228D0 (no) 2,4-diaminopyrimidin-derivater som dopamin D4 resepto-antagonister
SE0300120D0 (sv) Novel compounds
NO178259C (no) Amidinoforbindelser, farmasöytiske preparater inneholdende dem samt deres anvendelse i fremstilling av farmasöytiske preparater
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
MX9204858A (es) Mejoras en derivados de 2-(piperazinoalquil)indol condensados en posiciones 1,7, asi como un procedimiento y productos intermedios para su preparacion y medicamentos que contienen estos compuestos.
NO921159L (no) Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
ES543788A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo piridinometoxi sustituido y de sus sales deadicion acidas y cuaternarias
MY117936A (en) 1,3-dihydro-2h-imidazol-2-one derivatives
ATE244258T1 (de) Halo-derivate von 9-deoxo-9a-aza-9a- homerythromycin a
ES543793A0 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo piperidinopropanolico sustituido y sus sa- les de adicion acidas y amonicas cuaternarias
DK0570850T3 (da) Benzo(b)thiophen-3-yl-piperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
NO165593C (no) Analogifremgangsmaate ved fremstilling av nye tetracykliske indolderivater.
NO20053302D0 (no) Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
DE69000806D1 (de) Indol-derivate.
FR2823749B1 (fr) Phenyl- et pyridyl-piperidines, procede pour leur preparation et compositions pharmaceutiques les contenant